AYTU BIOPHARMA INC

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

AYTU$1.81+1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Consolidated Statements of Operations

(in thousands, except share and per share data)

	Three Months Ended
	September 30,
	2024	2023
Net revenue	$16,574	$17,817
Cost of sales	4,589	4,779
Gross profit	11,985	13,038
Operating expenses:
Selling and marketing	5,659	6,091
General and administrative	5,125	6,295
Research and development	426	595
Amortization of intangible assets	921	924
Restructuring costs	784	—
Total operating expenses	12,915	13,905
Loss from operations	(930)	(867)
Other income, net	542	584
Interest expense	(994)	(1,283)
Derivative warrant liabilities gain (loss)	2,880	(5,907)
Income (loss) from continuing operations before income tax expense	1,498	(7,473)
Income tax expense	(405)	—
Net income (loss) from continuing operations	1,093	(7,473)
Net income (loss) from discontinued operations, net of tax	381	(647)
Net income (loss)	$1,474	$(8,120)
Basic weighted-average common shares outstanding (note 17)	6,068,019	5,482,037
Diluted weighted-average common shares outstanding (note 17)	9,099,601	5,482,037
Net income (loss) per share (note 17):
Basic - continuing operations	$0.18	$(1.36)
Diluted - continuing operations	$(0.20)	$(1.36)
Basic - discontinued operations, net of tax	$0.06	$(0.12)
Diluted - discontinued operations, net of tax	$0.04	$(0.12)
Basic - net income (loss)	$0.24	$(1.48)
Diluted - net loss	$(0.15)	$(1.48)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.